medcheck™ from dnalife

PATIENT INFORMATION
NAME: Sample Patient
DOB: 01/Jan/1970
SEX AT BIRTH: Male

SPECIMEN DETAILS
BARCODE: TST-DL-SAMPLE
SAMPLE ID: 00001
TYPE: DBS
COLLECTED: 13/Aug/2024

ORDERED BY
Nordic Laboratories
REPORT GENERATED: 13/Aug/2024

Summary of Genetic Lab Data & Phenotypes

Gene	Allele Result	Phenotype Result
CYP3A4	*1/*1	Normal Metabolizer
CYP2D6	*4/*4	Poor Metabolizer
CYP2C9	*1/*3	Intermediate Metabolizer
CYP2C19	*1/*1	Normal Metabolizer
SLCO1B1	*1/*1	Normal Function
CYP2B6	*1/*1	Normal Metabolizer
CYP3A5	*3/*3	Poor Metabolizer

This is a short summary of the full medication report. The patient's results are now accessible within the clinical decision support software, TreatGx and ReviewGx, and can be used with other clinical information to enable precision prescribing and medication management. The final genotype/phenotype call is at the discretion of the laboratory director. Medication changes should only be initiated at the discretion of the patient's healthcare provider after a full assessment.

Methods

DNA was extracted from dried blood spot (DBS) card by Chemagic 360 system (Revvity) and processed in a Biomark X platform (Standard Biotools) with Advanta™ Pharmacogenomics Assay.

Limitations

The annotations and interpretations provided in this report are based on scientific literature and do not take into account drug-drug interactions, medical conditions or other clinical factors that may affect medication response. Gene-drug interactions are ranked according to guidelines, level of evidence and clinical utility. GenXys reports and TreatGx Clinical Decision Support are regularly updated. Current predicted phenotype and allele functionality may change in the future depending on new evidence. Phenotype annotations for CYP2C9 are based on total activity scores as defined by CPIC[79]. Genetic test results and interpretation may be inaccurate for individuals who have undergone or are receiving non-autologous blood transfusion, tissue, or organ transplant therapies.

The report includes alleles of proteins involved in the metabolism of many medications. In rare cases, a variant that is not covered may be typed as *1 or other variants. In the case of pseudogenes and mutations in the untranslated regions of genes, incorrect allele typing may occur despite proper SNP detection. Preferential amplification of one allele over another present in the sample may also lead to incorrect genotyping.

Liability Disclaimer

This test was developed and its performance characteristics determined by GenXys Health Care Systems. It has not been cleared or approved by the US Food and Drug Administration. The report is not a diagnostic test, and TreatGx is not a prescribing system. You should discuss your pharmacogenetic information with a physician or other health care provider before you act upon the pharmacogenetic information resulting from this report. The medication brand names are not an exhaustive list and do not include combination therapies. Not all medications in this report are included in the TreatGx or ReviewGx software or other GenXys derivative works.



Dr Juha Matilainen, Laboratory Director, PhD

13/Aug/2024

Date of Signature

medcheck™ from dnalife

PATIENT INFORMATION
NAME: Sample Patient
DOB: 01/Jan/1970
SEX AT BIRTH: Male

SPECIMEN DETAILS
BARCODE: TST-DL-SAMPLE
SAMPLE ID: 00001
TYPE: DBS
COLLECTED: 13/Aug/2024

ORDERED BY
Nordic Laboratories
REPORT GENERATED: 13/Aug/2024

Medication Summary Table

	1 Mild or no known interaction	2 Moderate gene-drug interaction: Consider alternative medications	2 Moderate gene-drug interaction: May require an increased dose	2 Moderate gene-drug interaction: May require a reduced dose	2 Moderate gene-drug interaction: May reduce efficacy	2 Moderate gene-drug interaction: May increase adverse events	3 Serious drug-gene interaction: evaluate and consider alternative medications
Analgesia	Carisoprodol Hydrocodone	Piroxicam Tenoxicam Venlafaxine		Alfentanil Celecoxib Fentanyl Flurbiprofen Ibuprofen Meloxicam Morphine Oliceridine	Fentanyl	Celecoxib Flurbiprofen Ibuprofen Meloxicam Oliceridine Piroxicam Tenoxicam Venlafaxine	Amitriptyline Codeine Desipramine Imipramine Nortriptyline Tramadol
Autoimmune	Tacrolimus			Cyclosporine Siponimod		Methotrexate Siponimod	
Cancer	Erdafitinib					Gefitinib Methotrexate	Tamoxifen
Cardiovascular	Atorvastatin Clopidogrel Lovastatin Mavacamten Nebivolol Pitavastatin	Fluvastatin	Warfarin	Flecainide Fluvastatin Propafenone Warfarin	Warfarin	Carvedilol Flecainide Fluvastatin Propafenone Warfarin	Metoprolol

medcheck™ from dnalife

PATIENT INFORMATION
NAME: Sample Patient
DOB: 01/Jan/1970
SEX AT BIRTH: Male

SPECIMEN DETAILS
BARCODE: TST-DL-SAMPLE
SAMPLE ID: 00001
TYPE: DBS
COLLECTED: 13/Aug/2024

ORDERED BY
Nordic Laboratories
REPORT GENERATED: 13/Aug/2024

	1 Mild or no known interaction	2 Moderate gene-drug interaction: Consider alternative medications	2 Moderate gene-drug interaction: May require an increased dose	2 Moderate gene-drug interaction: May require a reduced dose	2 Moderate gene-drug interaction: May reduce efficacy	2 Moderate gene-drug interaction: May increase adverse events	3 Serious drug-gene interaction: evaluate and consider alternative medications
	Pravastatin Propranolol Rosuvastatin Simvastatin						
Endocrinology	Nateglinide						
Gastroenterology	Esomeprazole Ondansetron Rabeprazole		Dexlansoprazole Lansoprazole Omeprazole Pantoprazole	Dronabinol Meclizine Metoclopramide	Dexlansoprazole Lansoprazole Omeprazole Pantoprazole	Dronabinol Meclizine Methotrexate Metoclopramide	
Infection	Efavirenz Voriconazole						
Mental Health	Amoxapine Citalopram Diazepam Escitalopram Methylphenidate Nicotine replacement therapy Protriptyline Quetiapine Sertraline	Fluvoxamine Venlafaxine Vortioxetine		Amphetamine Aripiprazole Aripiprazole lauroxil Atomoxetine Brexpiprazole Clozapine Fluvoxamine Haloperidol Iloperidone	Atomoxetine Bupropion	Amphetamine Aripiprazole Atomoxetine Fluvoxamine Haloperidol Iloperidone Lofexidine Paroxetine Perphenazine	Amitriptyline Clomipramine Desipramine Doxepin Imipramine Nortriptyline Thioridazine Trimipramine

medcheck™ from dnalife

PATIENT INFORMATION
NAME: Sample Patient
DOB: 01/Jan/1970
SEX AT BIRTH: Male

SPECIMEN DETAILS
BARCODE: TST-DL-SAMPLE
SAMPLE ID: 00001
TYPE: DBS
COLLECTED: 13/Aug/2024

ORDERED BY
Nordic Laboratories
REPORT GENERATED: 13/Aug/2024

	1 Mild or no known interaction	2 Moderate gene-drug interaction: Consider alternative medications	2 Moderate gene-drug interaction: May require an increased dose	2 Moderate gene-drug interaction: May require a reduced dose	2 Moderate gene-drug interaction: May reduce efficacy	2 Moderate gene-drug interaction: May increase adverse events	3 Serious drug-gene interaction: evaluate and consider alternative medications
	Viloxazine			Lofexidine Paroxetine Pimozide Risperidone Vortioxetine Zuclopenthixol		Risperidone Venlafaxine Vortioxetine Zuclopenthixol	
Neurology	Brivaracetam Clobazam Diazepam Donepezil Galantamine Propranolol	Venlafaxine		Deutetrabenazine Fosphenytoin Phenytoin Pitolisant Tetrabenazine Valbenazine	Fosphenytoin Phenytoin	Deutetrabenazine Fosphenytoin Phenytoin Tetrabenazine Valbenazine Venlafaxine	Amitriptyline Metoprolol
Other	Abrocitinib Avatrombopag Elagolix Eltrombopag Flibanserin Lusutrombopag Oral contraceptives					Cevimeline	Eliglustat
Rheumatology		Piroxicam Tenoxicam		Celecoxib Flurbiprofen Ibuprofen		Celecoxib Flurbiprofen Ibuprofen	

medcheck™ from dnalife

PATIENT INFORMATION
NAME: Sample Patient
DOB: 01/Jan/1970
SEX AT BIRTH: Male

SPECIMEN DETAILS
BARCODE: TST-DL-SAMPLE
SAMPLE ID: 00001
TYPE: DBS
COLLECTED: 13/Aug/2024

ORDERED BY
Nordic Laboratories
REPORT GENERATED: 13/Aug/2024

	1 Mild or no known interaction	2 Moderate gene-drug interaction					3 Serious drug-gene interaction: evaluate and consider alternative medications
		Consider alternative medications	May require an increased dose	May require a reduced dose	May reduce efficacy	May increase adverse events	
				Meloxicam		Meloxicam Methotrexate Piroxicam Tenoxicam	
Urology	Darifenacin Fesoterodine Mirabegron Tamsulosin				Tolterodine	Tolterodine	